FDA Under Pressure On Its Approach To Assigning Combo Product Jurisdiction
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal court handed down a potentially significant ruling related to FDA’s policies for designating primary product review responsibility to the drug, biologic or device center just days after members of Congress questioned FDA on its approach.
You may also be interested in...
Combination Products: Everyone Wants to Be a Device
Part of the fun of having a combination product is requesting a designation for your product to see what center will review it. Not surprisingly, most companies hope for CDRH.
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.
Regulatory News In Brief
Breast implant advisory panel